"The U.S. Food and Drug Administration today approved the first generic versions of Cymbalta (duloxetine delayed-release capsules), a prescription medicine used to treat depression and other conditions.
Aurobindo Pharma Ltd., Dr. Reddy's La"...
There is limited clinical experience with FETZIMA overdose in humans. In clinical studies, cases of ingestions up to 360 mg daily were reported with none being fatal.
Management of Overdose
No specific antidotes for FETZIMA are known. In managing overdose, provide supportive care, including close medical supervision and monitoring, and consider the possibility of multiple drug involvement. In case of an overdose, consult a Certified Poison Control Center (1-800-222-1222) for up-to-date guidance and advice. The high volume of distribution of levomilnacipran suggests that dialysis will not be effective in reducing levomilnacipran plasma concentrations.
- Hypersensitivity to levomilnacipran, milnacipran HCl or to any excipient in the formulation.
- The use of MAOIs intended to
treat psychiatric disorders with FETZIMA or within 7 days of stopping treatment
with FETZIMA is contraindicated because of an increased risk of serotonin
syndrome. The use of FETZIMA within 14 days of stopping an MAOI intended to
treat psychiatric disorders is also contraindicated [see DOSAGE AND ADMINISTRATION and WARNINGS AND PRECAUTIONS].
Starting FETZIMA in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see DOSAGE AND ADMINISTRATION and WARNINGS AND PRECAUTIONS].
- Uncontrolled Narrow-Angle Glaucoma: Do not use FETZIMA in patients with uncontrolled narrow-angle glaucoma. In clinical studies, FETZIMA was associated with an increased risk of mydriasis. Mydriasis has been reported with other SNRIs and FETZIMA [see WARNINGS AND PRECAUTIONS].
Last reviewed on RxList: 8/7/2013
This monograph has been modified to include the generic and brand name in many instances.
Additional Fetzima Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get tips on therapy and treatment.